Original Article

Associations Between Safety of Certolizumab Pegol, Disease Activity, and Patient Characteristics, Including Corticosteroid Use and Body Mass Index

First published: 01 July 2021https://doi.org/10.1002/acr2.11259
Supported by UCB Pharma. Prof. Jeffrey R. Curtis has received grant/research support from Abbvie, Amgen, Bristol-Myers Squibb, Corrona, Crescendo, Genentech, Janssen, Pfizer, Roche, and UCB Pharma. Dr. Xavier Mariette is supported by Biogen, Pfizer, and UCB Pharma. Dr. Boulos Haraoui has received grant/research support from Abbott, Amgen, Bristol-Myers Squibb, Janssen, Pfizer, Roche, and UCB Pharma.

Get access to the full version of this article. View access options below.

Institutional Login
Access through Oxford Brookes University

or log in with a different institution

Log in with AAA

Log in with your society credentials.

Log in to Wiley Online Library

If you have previously obtained access with your personal account, please log in.

Purchase instant access
48-Hour online access
$7.00
  • View the article PDF and any associated supplements and figures for a period of 48 hours.
  • Article can not be printed.
  • Article can not be downloaded.
  • Article can not be redistributed.
Online only acccess
$16.00
  • Unlimited viewing of the article PDF and any associated supplements and figures.
  • Article can not be printed.
  • Article can not be downloaded.
  • Article can not be redistributed.
Full text and PDF download
$42.00
  • Unlimited viewing of the article/chapter PDF and any associated supplements and figures.
  • Chapter can be printed.
  • Chapter can be downloaded.
  • Chapter can not be redistributed.
Check out

Abstract

Objective

To examine relationships between knee osteoarthritis (KOA) and obesity, diabetes mellitus (DM), and cardiovascular disease (CVD).

Methods

Associations of time-dependent obesity, DM, and CVD with KOA transition states over approximately 18 years were examined among 4093 participants from a community-based cohort. Transition states were 1) no knee symptoms and no radiographic KOA (rKOA; Kellgren-Lawrence grade ≥2 in at least one knee), 2) asymptomatic rKOA, 3) knee symptoms only, 4) symptomatic rKOA (sxKOA; rKOA and symptoms in same knee). Markov multistate models estimated adjusted hazard ratios (aHRs) and 95% confidence intervals (CIs) for associations between comorbid conditions and transitions across states, adjusting for baseline age, sex, race, education, enrollment cohort, birth year, and time-dependent knee injury history.

Results

At baseline, 40% of participants had obesity, 13% had DM, and 22% had CVD (mean age = 61 years; 34% Black; 37% male). Compared with those without obesity, those with obesity had a higher hazard of worsening from no rKOA/no symptoms to asymptomatic rKOA (aHR = 1.7; 95% CI = 1.3-2.2) and from knee symptoms to sxKOA (aHR = 1.7; 95% CI = 1.3-2.3), as well as a lower hazard of symptom resolution from sxKOA to asymptomatic rKOA (aHR = 0.5 [95% = CI 0.4-0.7]). Compared with those without CVD, those with CVD had a higher hazard of worsening from no rKOA/symptoms to knee symptoms (aHR = 1.5; 95% CI = 1.1-2.1). DM was not associated with transitions of rKOA.

Conclusion

Prevention of obesity and CVD may limit the development or worsening of rKOA and symptoms.

Conflicts of interest

The authors declare no conflicts of interest.

Volume 3, Issue 11

November 2021

Pages 765-770

Advertisement